Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP)
Cerebral Ventricle Neoplasms
© 2020 British Society for Haematology and John Wiley & Sons Ltd Care of patients with chronic immune thrombocytopenia (ITP) who are refractory to available treatments can be quite challenging. Fostamatinib, an oral Syk inhibitor, is the newest FDA-approved agent for ITP. Phase 3 clinical trials demonstrated an overall response in 43% of patients treated with fostamatinib and use for two years has been reported. Herein, we report two patients with long histories of ITP without lasting responses to numerous first-, second- and third-line therapies with prolonged responses to ongoing fostamatinib. This shows that patients unresponsive to other agents may respond to fostamatinib and can have sustained benefit.
Digital Object Identifier (DOI)